Bloating, reflux, transit: what really changes in your belly
In the morning your trousers close, in the evening they do not. This is not fat: fat does not appear in ten hours. What perimenopause really changes about digestion, and three things that surprise: the peak is during the crossing and not after, what worsens later is the pelvic floor and not the gut, and the microbiome rests on far less evidence than it is sold on. In French with English subtitles.
Watch on YouTube (full description and references) →
Read the written and sourced version of this topic →
What you will understand
The trousers that closed at eight in the morning and will not close at six in the evening, the belt loosened a notch by the end of the day, a belly that looks twice its size although nothing has happened. First thing to settle: this is not fat. Fat does not appear in ten hours. What changes volume within a single day is gas, water and the contents of the gut, and that is exactly what perimenopause disturbs.
These symptoms are real, and you are not imagining them. The first serious work on this dates from 1998: two hundred and twenty-eight women from an American gastroenterology practice, which is few and comes from a single centre, but with a clear denominator. Thirty-eight percent of the postmenopausal women reported altered bowel habits against fourteen percent before menopause, forty-eight percent reported gas, thirty-four percent heartburn or regurgitation, and complaints suggesting irritable bowel peaked between forty and forty-nine years of age (PMID 9796084). The mechanism is not mysterious: the digestive tract carries estrogen receptors, and a signal that fluctuates gives motility that fluctuates. The weakness of this literature also has to be said, because nobody says it: a scoping review published in 2025 went through one hundred and twenty-two studies published between 1981 and 2024 and concludes that constipation is by far the most studied symptom, that menopausal stages are poorly reported, and that the evidence gaps remain large (PMID 41143477).
First surprise, and it runs against the usual story that it will only get worse: the hardest moment is not after menopause, it is during the crossing. The Rome Foundation Global Epidemiology Survey, fourteen thousand five hundred and seventy people across twenty-six countries, shows that digestive symptoms are on the whole more marked in women who have not yet reached menopause, which points to sharper visceral perception during the transition rather than to a slope that only goes down (PMID 39748465). In other words, you are going through turbulence, not down a slope.
Second surprise: what gets worse afterwards is not the gut, it is the exit. In that same survey, postmenopausal women reported more stool leakage and more manual manoeuvres to pass a stool, eighteen percent against twenty-five percent among the women affected by functional constipation (PMID 39748465). This is not the colon, it is the pelvic floor and ano-rectal function. It is rarely said, and it is the good news of the topic, because it can be retrained: a midwife or a physiotherapist specialised in the pelvic floor is the right referral, and there is no reason to wait.
Third surprise, the most commercial one: the microbiome. The underlying biology is solid. Bacterial enzymes in the gut, the beta-glucuronidases, reactivate the estrogens that the liver had neutralised, which was demonstrated at molecular level in 2019 (PMID 31636122), and a 2017 review set out the framework of this estrogen-microbiome axis (PMID 28778332). The missing step is the next one. When you look at what has actually been measured in women before and after menopause, the available meta-analysis rests on three case-control studies and one hundred and fifty-six people in total, finds no difference at phylum level, a non-significant diversity index, and only a few genera that vary (PMID 35923245). Three studies and one hundred and fifty-six women: that is not nothing, but it does not justify half the supplement aisle.
Hormone therapy, for its part, is not a treatment for digestion, and that has to be said in both directions. Above all, never stop a treatment because you watched a video: its indication remains hot flashes, and the decision is made with your doctor. As early as 1998, taking estrogen did not change the digestive symptoms of the women followed (PMID 9796084). On reflux, a 2023 meta-analysis finds odds about twenty-nine percent higher among users, with a 95% confidence interval of 1.17 to 1.42, but heterogeneity of 94.8% that leads the authors themselves to caution: this is an association, not causation (PMID 37369078). On the gallbladder, the randomised trials of the Women's Health Initiative show a higher risk under conjugated estrogens, with a hazard ratio of 1.67 (PMID 15657326), and the Million Women Study, covering more than a million women, finds a relative risk of 1.64 with a clear difference between the transdermal route, at 1.17, and the oral route, at 1.74 (PMID 18617493). That patch-versus-tablet nuance is a conversation to have with your doctor, not a recommendation. Finally, the link between body mass index and reflux is clear and dose-dependent, stronger in women, and it is given here as an association and not as an instruction to lose weight (PMID 12837713).
That leaves what actually works. A non-inferiority randomised trial published in 2025 in one hundred and thirty-nine people with irritable bowel syndrome, mean age forty, shows that the Mediterranean diet is not only non-inferior but superior to standard dietary advice, with twenty percentage points more responders, confidence interval 4 to 36, P equal to 0.017 (PMID 41144975). The low FODMAP diet ranks first in a network meta-analysis of thirteen trials and nine hundred and forty-four patients, provided it is done in stages and with a professional, never for life (PMID 34376515). Brain-gut therapies work, with minimal-contact cognitive behavioural therapy giving a relative risk of 0.55, confidence interval 0.39 to 0.76, and the authors acknowledge limited confidence and publication bias (PMID 41077057). Probiotics, finally: eighty-two trials and ten thousand three hundred and thirty-two patients show that some strains help, that the effect is strain-dependent, and that trial quality is often limited (PMID 37541528). This is not a treatment: if nothing has changed in four to six weeks, stop. Two false leads come up constantly and deserve their own video: the thyroid and ferritin. And one rule that overrides everything else: blood in the stool, weight loss you did not seek, anaemia, first symptoms appearing after fifty, a family history of colorectal cancer or inflammatory bowel disease, or difficulty swallowing, none of that is tested with a diet; it is seen by a doctor and investigated (PMID 33315591).
The key points to remember
- A belly that swells during the day is not fat: fat does not appear in ten hours. What changes volume is gas, water and the contents of the gut.
- These symptoms have been documented since 1998, with a clear denominator, but the literature remains thin: a 2025 scoping review says so plainly.
- The hardest moment is not after menopause, it is during the crossing: in the Rome Foundation global survey, symptoms are on the whole more marked before menopause.
- What gets worse afterwards is not the colon but the exit: stool leakage and manual manoeuvres increase, which is a pelvic floor matter, and it can be retrained.
- The microbiome is real biology attached to marketing far ahead of the evidence: the available meta-analysis rests on three studies and one hundred and fifty-six women.
- Hormone therapy is not a treatment for digestion: it is associated with more reflux and more gallbladder disease, with a patch-versus-tablet difference to discuss with your doctor.
- What has the most evidence: the Mediterranean pattern, a supervised and staged low FODMAP diet, brain-gut therapies, and probiotics tried for four to six weeks then stopped if nothing changes.
- The signals that call for a consultation: blood in the stool, unsought weight loss, anaemia, first symptoms after fifty, a family history of colorectal cancer or inflammatory bowel disease, difficulty swallowing.
Video chapters
- 0:00 This is not fat
- 1:16 It is real, you are not imagining it
- 3:04 The hardest moment is not the one you think
- 4:37 What gets worse is the exit
- 5:38 Microbiome: the real biology, then the marketing
- 7:28 Hormone therapy does not fix your belly
- 9:33 What actually works
- 11:28 The signs that call for a doctor
The scientific sources cited
Every claim in this video rests on a verified reference. Here is the complete list, with the PubMed links.
- Sarnoff RP, et al. Sex Differences, Menses-Related Symptoms and Menopause in Disorders of Gut-Brain Interaction. Neurogastroenterol Motil. 2025. PubMed 39748465
- Shaw N, Abbott R, Pettinger C. The volume and characteristics of research on gastrointestinal symptoms in 'natural' peri- and postmenopause: a scoping review. Womens Health (Lond). 2025. PubMed 41143477
- Bamidele JO, et al. The Mediterranean Diet for Irritable Bowel Syndrome: A Randomized Clinical Trial. Ann Intern Med. 2025. PubMed 41144975
- Thakur ER, et al. Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2025. PubMed 41077057
- Goodoory VC, et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023. PubMed 37541528
- Aldhaleei WA, et al. The association between menopausal hormone therapy and gastroesophageal reflux disease: a systematic review and meta-analysis. Menopause. 2023. PubMed 37369078
- Yang M, et al. Systematic Review and Meta-analysis: Changes of Gut Microbiota before and after Menopause. Dis Markers. 2022. PubMed 35923245
- Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022. PubMed 34376515
- Lacy BE, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021. PubMed 33315591
- Ervin SM, et al. Gut microbial beta-glucuronidases reactivate estrogens as components of the estrobolome. J Biol Chem. 2019. PubMed 31636122
- Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017. PubMed 28778332
- Liu B, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008. PubMed 18617493
- Cirillo DJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005. PubMed 15657326
- Nilsson M, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003. PubMed 12837713
- Triadafilopoulos G, Finlayson M, Grellet C. Bowel dysfunction in postmenopausal women. Women Health. 1998. PubMed 9796084
Frequently asked questions
My belly swells during the day: am I putting on weight?
No, not on that timescale. Fat is not laid down in ten hours. A belly that is flat in the morning and distended in the evening changes volume because of gas, water and the contents of the gut, not because of fat mass. That does not rule out weight gain elsewhere, but they are two different phenomena, and confusing them leads to treating the wrong problem.
Will it get worse after menopause?
Not in the way the story is usually told. In the Rome Foundation global survey, covering fourteen thousand five hundred and seventy people across twenty-six countries, digestive symptoms were on the whole more marked in women who had not yet reached menopause. What increases afterwards is stool leakage and the need for manual manoeuvres, that is, a pelvic floor problem rather than a gut problem. That is good news, because it can be retrained.
Are probiotics worth it?
Sometimes, and in a highly strain-dependent way. A meta-analysis of eighty-two trials and ten thousand three hundred and thirty-two patients shows that some strains or combinations help, with trial quality often limited. It is not a treatment, it is a personal trial: give a product four to six weeks, and stop if nothing changes. And the menopause microbiome itself rests on three studies and one hundred and fifty-six women, which is very little given what is being sold.
Will hormone therapy fix my bloating?
No, that is not its indication, and you should not stop it or start it for that reason without talking to your doctor. As early as 1998, taking estrogen did not change digestive symptoms. It is, however, associated with more reflux, with odds about twenty-nine percent higher, and with more gallbladder disease, with a clear difference between the transdermal and the oral route. These are associations, to be weighed against the expected benefit on hot flashes, with your doctor.
Should I follow a low FODMAP diet?
It is the best ranked dietary approach in network meta-analyses on irritable bowel syndrome, but it comes with conditions: it is done in stages, with a professional, and above all it is not kept for life, because the exclusion phase is restrictive and impoverishes the diet. A 2025 randomised trial also shows that the Mediterranean diet does better than standard dietary advice, with twenty percentage points more responders: it is often an easier starting point to sustain.
Which signs mean I should see a doctor without waiting?
Blood in the stool, weight loss you did not seek, anaemia, first digestive symptoms appearing after fifty, a family history of colorectal cancer or inflammatory bowel disease, or difficulty swallowing. In those situations you do not test diets: you see a doctor and investigate. And colorectal cancer screening has a starting age, which is worth checking with your doctor rather than putting off.